IR News

CHEPLAPHARM continues on the road to success

 

Greifswald  – CHEPLAPHARM consistently implements its growth strategy in 2020 and increases turnover by over 30% to € 680 million.

 

 

With the…

Read more  /  pdf

Changes of Management Board per April

 

CHEPLAPHARM is delighted to announce an addition to its board of management.

With effect of April 1st, 2021 Dr. Keyarasch “Kia” Parssanedjad, M.D.…

Read more  /  pdf

Changes of CHEPLAPHARM Management Board per March

 

Greifswald – 1st March 2021

 

CHEPLAPHARM is delighted to herewith inform of the change of its board of management.

With effect as of 1st of March…

Read more  /  pdf

CHEPLAPHARM Arzneimittel GmbH Announces Receipt of Required Consents

 

CHEPLAPHARM Arzneimittel GmbH

CHEPLAPHARM Arzneimittel GmbH Announces Receipt of Required Consents in Connection with the
Consent Solicitation…

Read more  /  pdf

CHEPLAPHARM Arzneimittel GmbH Announces Consent Solicitation

 

CHEPLAPHARM Arzneimittel GmbH

CHEPLAPHARM Arzneimittel GmbH Announces Consent Solicitation Relating to its

3.500% Senior Secured Notes due 2027

Read more  /  pdf

CHEPLAPHARM acquires rights to Rivotril®

 

Greifswald, 01/11/2021 - CHEPLAPHARM expanded its portfolio by acquiring the commercial rights for Rivotril® from Roche.

 

 

"As a successful start…

Read more  /  pdf

CHEPLAPHARM completes it´s largest acquisition so far

 

Greifswald, 01/05/2021 - CHEPLAPHARM successfully closes acquisition of cardiovascular and metabolic portfolio from Takeda

 

Last week CHEPLAPHARM…

Read more  /  pdf

CHEPLAPHARM acquires rights to Atacand® in more than 70 markets

 

Greifswald, 01/04/2021 - Cheplapharm acquires the global rights for the products Atacand® and Atacand® Plus

 

CHEPLAPHARM has held the rights for…

Read more  /  pdf

2020

CHEPLAPHARM proves its vigour

 

Cheplapharm successfully closes the first project with LEO Pharma

 

This week CHEPLAPHARM successfully closed the project with LeoPharma, which…

Read more  /  pdf

CHEPLAPHARM closes another product portfolio acquisition

 

This week Cheplapharm closed another deal of a product bundle which contains six molecules and 12 related brands, focused on the treatment of…

Read more  /  pdf

CHEPLAPHARM succeeds again: 1 Billion Euros (equivalent) of Senior Secured Notes placed with institutional Investors

CHEPLAPHARM Arzneimittel GmbH has successfully gained a foothold in the US American institutional bond market.

Read more  /  pdf

CHEPLAPHARM announces pricing of Senior Secured Notes

CHEPLAPHARM Arzneimittel GmbH Announces Pricing of

€575 Million 4.375% Senior Secured Notes due 2028

$500 Million 5.500% Senior Secured Notes due…

Read more  /  pdf

CHEPLAPHARM - Quarterly Update Call Q4 / FY 2019

Cheplapharm Arzneimittel GmbH - Quarterly Update Call Q4 / FY 2019

| Wednesday, 08 April 2020, 10:30 BST | 11:30 CEST

Read more  /  pdf

Corona Virus (COVID-19) Impact on CHEPLAPHARM activities

Due to the COVID-19 situation, CHEPLAPHARM Arzneimittel GmbH is closely monitoring the potential

impact on the various Supply Chains and is committed…

Read more  /  pdf

CHEPLAPHARM’s successful institutional bond debut: 500 million euros of senior secured notes at 3.500% placed with institutional investors

CHEPLAPHARM Arzneimittel GmbH, a repeat issuer in the long-term loan market with 980 million euros of institutional term loan (“TLB”) outstanding,…

Read more  /  pdf

CHEPLAPHARM announces pricing of Senior Secured Notes

Cheplapharm has priced €500 million aggregate principal amount of its 3.500% senior secured notes due 2027 (the “Notes”), at an offering price of…

Read more  /  pdf

CHEPLAPHARM announces offering of Senior Secured Notes

Cheplapharm Arzneimittel GmbH has launched an offering of €400 million aggregate principal amount of senior secured notes due 2027.

Read more  /  pdf

2019

CHEPLAPHARM's third capital market transaction five times oversubscribed

London/Greifswald, June 13, 2019 – CHEPLAPHARM Arzneimittel GmbH very successfully closed its third capital markets transaction within just one year.…

Read more  /  pdf

2018

CHEPLAPHARM places additional € 300 million capital market loan in London with Institutional Investors

Following a successful roadshow with Institutional Investors in London, CHEPLAPHARM Arzneimittel GmbH was able to issue another loan (TLB market) in…

Read more  /  pdf

CHEPLAPHARM’s successful Capital Markets debut: 780 million euros new lending facilities agreed and thus future financing sources secured

CHPLAPHARM Arzneimittel GmbH has successfully completed the refinancing of existing loans and promissory notes.

Read more  /  pdf

CHEPLAPHARM receives credit ratings: A premiere for a medium-sized company in Mecklenburg-Western Pomerania

In the course of an external credit rating, CHEPLAPHARM is rated B/B1 - and thus stable future outlooks.

Read more  /  pdf